111 Debt to Equity Ratio 2018-2023 | YI
Current and historical debt to equity ratio values for 111 (YI) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. 111 debt/equity for the three months ending September 30, 2023 was 0.00.
| 111 Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-09-30 | $0.53B | $-0.07B | -7.52 |
| 2023-06-30 | $0.48B | $-0.06B | -7.87 |
| 2023-03-31 | $0.53B | $-0.06B | -8.73 |
| 2022-12-31 | $0.56B | $-0.06B | -9.50 |
| 2022-09-30 | $0.48B | $-0.05B | -9.47 |
| 2022-06-30 | $0.51B | $-0.05B | -11.27 |
| 2022-03-31 | $0.51B | $-0.04B | -13.66 |
| 2021-12-31 | $0.52B | $-0.02B | -21.68 |
| 2021-09-30 | $0.50B | $-0.01B | -57.57 |
| 2021-06-30 | $0.49B | $0.03B | 19.11 |
| 2021-03-31 | $0.43B | $0.05B | 9.52 |
| 2020-12-31 | $0.40B | $0.06B | 6.45 |
| 2020-09-30 | $0.33B | $0.07B | 4.69 |
| 2020-06-30 | $0.18B | $0.08B | 2.19 |
| 2020-03-31 | $0.14B | $0.10B | 1.46 |
| 2019-12-31 | $0.12B | $0.11B | 1.08 |
| 2019-09-30 | $0.10B | $0.13B | 0.78 |
| 2019-06-30 | $0.10B | $0.15B | 0.68 |
| 2019-03-31 | $0.08B | $0.16B | 0.46 |
| 2018-09-30 | $0.05B | $0.19B | 0.27 |
| 2018-06-30 | $0.32B | $-0.16B | -2.02 |
| 2017-12-31 | $0.26B | $-0.14B | -1.81 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.081B | $2.105B |
| 111, Inc. operates as a digital and mobile healthcare platform. The Company offers pharmacy distribution, medical consultancy, e-prescription and other services. 111, Inc. is headquartered in Shanghai, China. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GE HealthCare Technologies (GEHC) | United States | $38.875B | 21.62 |
| Inspire Medical Systems (INSP) | United States | $7.378B | 0.00 |
| 10x Genomics (TXG) | United States | $3.475B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $3.470B | 0.00 |
| Axonics (AXNX) | United States | $3.427B | 0.00 |
| Enovis (ENOV) | United States | $3.084B | 23.43 |
| Azenta (AZTA) | United States | $2.854B | 232.59 |
| Olink Holding AB (publ) (OLK) | Sweden | $2.772B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $2.659B | 0.00 |
| Privia Health (PRVA) | United States | $2.118B | 93.95 |
| Schrodinger (SDGR) | United States | $1.811B | 0.00 |
| Phreesia (PHR) | United States | $1.306B | 0.00 |
| Omnicell (OMCL) | United States | $1.206B | 29.52 |
| Definitive Healthcare (DH) | United States | $0.847B | 0.00 |
| Standard BioTools (LAB) | United States | $0.757B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.601B | 0.00 |
| Talkspace (TALK) | United States | $0.497B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.329B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.316B | 0.00 |
| Clover Health Investments (CLOV) | United States | $0.308B | 0.00 |
| Pulmonx (LUNG) | United States | $0.286B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.171B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.158B | 0.00 |
| Augmedix (AUGX) | United States | $0.155B | 0.00 |
| American Well (AMWL) | United States | $0.149B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.131B | 0.00 |
| TruBridge (TBRG) | United States | $0.122B | 5.19 |
| Outset Medical (OM) | United States | $0.112B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.076B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.076B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.051B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.042B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.033B | 0.00 |
| Movano (MOVE) | United States | $0.026B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| Cue Health (HLTH) | United States | $0.023B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.021B | 0.00 |
| ETAO (ETAO) | United States | $0.019B | 0.00 |
| CareCloud (CCLD) | United States | $0.019B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.018B | 0.00 |
| Akili (AKLI) | United States | $0.017B | 0.00 |
| Centogene (CNTG) | Germany | $0.013B | 0.00 |
| Biotricity (BTCY) | United States | $0.012B | 0.00 |
| Transgenomic (PRPO) | United States | $0.010B | 0.00 |
| Syra Health (SYRA) | United States | $0.007B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Zhongchao (ZCMD) | China | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |